CD38 — a new target in renal immune disease

IF 28.6 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Nephrology Pub Date : 2024-07-23 DOI:10.1038/s41581-024-00874-6

Ton J. Rabelink, Aiko P. J. de Vries

引用次数: 0

Abstract

Targeting of CD38 has been posited as a potential therapeutic avenue for the treatment of immune-mediated conditions. A phase 2 study now reports promising safety, tolerability and intermediate endpoint of efficacy outcomes with the anti-CD38 monoclonal antibody felzartamab in kidney transplant recipients with antibody-mediated rejection.

Abstract Image

查看原文本刊更多论文

CD38--肾脏免疫疾病的新靶点。

靶向 CD38 被认为是治疗免疫介导疾病的一种潜在疗法。一项二期研究报告显示，抗 CD38 单克隆抗体 felzartamab 对抗体介导的排斥反应的肾移植受者具有良好的安全性、耐受性和中间终点疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Nephrology 医学-泌尿学与肾脏学

CiteScore

39.00

自引率

1.20%

发文量

127

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Nephrology aims to be the premier source of reviews and commentaries for the scientific communities it serves. It strives to publish authoritative, accessible articles. Articles are enhanced with clearly understandable figures, tables, and other display items. Nature Reviews Nephrology publishes Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements. The content is relevant to nephrologists and basic science researchers. The broad scope of the journal ensures that the work reaches the widest possible audience.